From Nobel laureates to visionary leaders to fearless patient advocates, the global oncology community has no shortage of trailblazers focused on fighting cancer. But we all know that creating truly transformative treatments and realizing the promise of precision medicine takes more than the brilliance of individuals; it requires the combined creativity and ingenuity of many. Indeed, the next stage of oncology research will, more than ever, be defined by collaborations that advance current science and pioneer new ways of working together.
You are here
Articles of Interest
Beijing hosted a landmark US-China summit on precision medicine this week. Government, academia and industry leaders from the two countries gathered for the event on 29 March, sponsored by Thermo Fisher Scientific, to discuss how to capitalise on the potential of precision medicine has to offer game changing solutions in the fight against cancer and other devastating diseases.
As administrations change, cancer research stands in an unusually strong position, NCI Acting Director Douglas Lowy said in an interview with The Cancer Letter.
View the CEO Roundtable on Cancer brochure.
The attack on Pearl Harbor 75 years ago drew a staggered, reluctant America headlong into the global struggle against the Axis powers. I was still in high school walking across the campus at Andover in Massachusetts when we heard the news.
In 1969, America put a man on the Moon, a breathtaking achievement that many said couldn’t be done. The great challenge of our lifetime is putting an end to cancer. This single disease kills an estimated 600,000 people every year. As with the Moon Shot, the nation must come together again, overcome the odds, and achieve the impossible.
"Enclaves" for cancer data that give access to participating researchers, cancer centers, pharma companies, and others can speed cancer therapy development.
The CEO Roundtable on Cancer has a storied fifteen-year history that proudly traces its origins to President George HW Bush.
CNBC interview with Mr. Christopher A. Viehbacher, Chief Executive Officer of Sanofi and chairman of the CEO Roundtable on Cancer.
Project Data Sphere, which launched on April 8, is a “giant digital laboratory, an enormous library containing data about tens of thousands of patients and hundreds of clinical trials, all of which will be in the public domain,” said Martin J. Murphy, Jr, DMedSc, PhD, FASCO, Chief Executive Officer of the CEO Roundtable on Cancer.
The answer, of course, is learning how to share. In medicine, the question is when, and how, to share data. The hope (and hype) of Big Data is that massive datasets can help researchers and companies slice and dice cancer into smaller, more manageable patient populations where companies can rapidly develop, test, and launch new cancer targeted drugs and diagnostics. The goal, of course, is to generate much better patient outcomes, at much lower cost, than the status quo.
Big Pharma spends billions of dollars each year researching, developing and testing new treatments for cancer. In the meantime, it’s also collecting millions of data points that figuratively sit on a shelf and collect dust once a clinical trial is complete. A consortium of Big Pharma companies and research organizations are attempting to give that raw data a second life by making it available to researchers on the new Project Data Sphere platform.
The initiative, announced today, will mark the launch of a new data sharing platform, with the goal of advancing research to improve the lives of cancer patients and their families around the world. The CEO Roundtable on Cancer was established in 2001 with the mandate to bring bold and imaginative solutions to cancer care.
The Life Sciences Consortium of the CEO Roundtable on Cancer today announced the launch of the Project Data Sphere initiative, a platform designed to facilitate the sharing, integration and analysis of data from phase 3, comparator arm cancer trials.